{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:41:50Z","timestamp":1792716110361,"version":"4.5.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T00:00:00Z","timestamp":1766707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"vor","delay-in-days":33,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Women's Health"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Uterine serous carcinoma (USC) is an aggressive subtype of endometrial cancer with high recurrence and mortality rates. HER2 overexpression and amplification represent important prognostic and predictive biomarkers in USC, supporting the use of HER2-targeted therapy. However, intratumoral heterogeneity and discrepancies between biopsy and hysterectomy specimens complicate accurate HER2 assessment. This study aimed to evaluate the diagnostic concordance of HER2 status between endometrial biopsy and resection samples using immunohistochemistry (IHC) and chromogenic in situ hybridization (CISH).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study included 40 patients diagnosed with USC (2010\u20132020). HER2, ER, PR, and Ki-67 were evaluated by IHC, and HER2 amplification was determined by CISH in all cases. Concordance between biopsy and resection specimens was assessed using Cohen\u2019s kappa coefficient, with resection CISH considered the gold standard. Associations between HER2 status and clinicopathologic variables were analyzed using chi-square and Mann\u2013Whitney U tests.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      HER2 gene amplification was identified in 20% of cases (8\/40). Biopsy CISH correctly detected 7 of 8 amplified tumors, yielding a positive predictive value (PPV) of 100% and a negative predictive value (NPV) of 97%. Only one true discordant case was observed. Concordance between biopsy and resection HER2 status was excellent (\u03ba\u2009=\u20090.918). HER2-positive tumors demonstrated significantly higher Ki-67 proliferation indices (median 77% vs. 67%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and were more frequently associated with advanced FIGO stage (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.045). No significant associations were found between HER2 status and ER, PR, or LVI.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Biopsy-based HER2 testing shows excellent concordance with resection specimens and reliably predicts HER2 amplification in USC. The findings highlight the utility of preoperative biopsies for HER2 assessment and affirm the importance of CISH confirmation in borderline (1\u2009+\u2009and 2+) IHC categories. Standardized HER2 testing criteria specific to USC remain essential to optimize patient selection for targeted therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12905-025-04235-8","type":"journal-article","created":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T11:45:13Z","timestamp":1766749513000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["HER2 evaluation in uterine serous carcinoma: diagnostic agreement between biopsy and resection samples"],"prefix":"10.1186","volume":"26","author":[{"given":"Zeynep","family":"Bayramoglu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denizhan","family":"Bayramoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safiye","family":"Aktas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,26]]},"reference":[{"key":"4235_CR1","unstructured":"Surveillance, Epidemiology and End Results Program. Cancer stat facts: uterine cancer. National Cancer Institute. https:\/\/seer.cancer.gov\/statfacts\/html\/corp.html. Accessed 28 Jan 2023."},{"issue":"2","key":"4235_CR2","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1006\/gyno.1997.4617","volume":"65","author":"RP Matthews","year":"1997","unstructured":"Matthews RP, Hutchinson-Colas J, Maiman M, et al. Papillary serous and clear cell type lead to poor prognosis of endometrial carcinoma in black women. Gynecol Oncol. 1997;65(2):206\u201312. https:\/\/doi.org\/10.1006\/gyno.1997.4617.","journal-title":"Gynecol Oncol"},{"issue":"5","key":"4235_CR3","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/sj.bjc.6603012","volume":"94","author":"CA Hamilton","year":"2006","unstructured":"Hamilton CA, Cheung MK, Osann K, et al. Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br J Cancer. 2006;94(5):642\u20136. https:\/\/doi.org\/10.1038\/sj.bjc.6603012.","journal-title":"Br J Cancer"},{"issue":"1","key":"4235_CR4","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.pathol.2022.11.004","volume":"55","author":"KL Talia","year":"2023","unstructured":"Talia KL, Banet N, Buza N. The role of HER2 as a therapeutic biomarker in gynaecological malignancy: potential for use beyond uterine serous carcinoma. Pathology. 2023;55(1):8\u201318.","journal-title":"Pathology"},{"issue":"1","key":"4235_CR5","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1097\/PGP.0000000000000711","volume":"40","author":"N Buza","year":"2021","unstructured":"Buza N. HER2 testing and reporting in endometrial serous carcinoma: practical recommendations for HER2 immunohistochemistry and fluorescent in situ hybridization: proceedings of the ISGyP companion society session at the 2020 USCAP annual meeting. Int J Gynecol Pathol. 2021;40(1):17\u201323. https:\/\/doi.org\/10.1097\/PGP.0000000000000711.","journal-title":"Int J Gynecol Pathol"},{"issue":"1","key":"4235_CR6","doi-asserted-by":"publisher","first-page":"18","DOI":"10.5858\/2007-131-18-ASOCCO","volume":"131","author":"AC Wolff","year":"2007","unstructured":"Wolff AC, Hammond ME, Schwartz JN, et al. American society of clinical Oncology\/College of American pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med. 2007;131(1):18\u201343.","journal-title":"Arch Pathol Lab Med"},{"issue":"11","key":"4235_CR7","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.5858\/arpa.2018-0902-SA","volume":"142","author":"AC Wolff","year":"2018","unstructured":"Wolff AC, Hammond MEH, Allison KH, et al. Human epidermal growth factor receptor 2 testing in breast cancer: ASCO\/CAP clinical practice guideline focused update. Arch Pathol Lab Med. 2018;142(11):1364\u201382.","journal-title":"Arch Pathol Lab Med"},{"issue":"7","key":"4235_CR8","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1038\/s41379-021-00761-2","volume":"34","author":"A Hodgson","year":"2021","unstructured":"Hodgson A, Parra-Herran C, Yemelyanova A, et al. Reproducibility of scoring criteria for HER2 immunohistochemistry in endometrial serous carcinoma: a multi-institutional interobserver agreement study. Mod Pathol. 2021;34(7):1274\u201383. https:\/\/doi.org\/10.1038\/s41379-021-00761-2.","journal-title":"Mod Pathol"},{"key":"4235_CR9","doi-asserted-by":"publisher","first-page":"100163","DOI":"10.1038\/s44276-025-00125-6","volume":"4","author":"K Aro","year":"2025","unstructured":"Aro K, Pasanen A, Leminen A, Loukovaara M, B\u00fctzow R. HER2 amplification and HER2-low expression in endometrial carcinoma: a population-based study. BJC Rep. 2025;4:100163. https:\/\/doi.org\/10.1038\/s44276-025-00125-6.","journal-title":"BJC Rep"},{"key":"4235_CR10","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ygyno.2024.12.012","volume":"178","author":"FE Odicino","year":"2025","unstructured":"Odicino FE, Bignotti E, Rossi E, et al. HER2 overexpression and amplification in uterine serous papillary carcinoma: correlation with clinicopathological features and outcome. Gynecol Oncol. 2025;178:78\u201385. https:\/\/doi.org\/10.1016\/j.ygyno.2024.12.012.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"4235_CR11","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1097\/IGC.0000000000000844","volume":"27","author":"M McGunigal","year":"2017","unstructured":"McGunigal M, Liu J, Kalir T, Chadha M, Gupta V. Survival differences among uterine papillary serous, clear cell and grade 3 endometrioid adenocarcinoma: a National cancer database analysis. Int J Gynecol Cancer. 2017;27(1):85\u201392. https:\/\/doi.org\/10.1097\/IGC.0000000000000844.","journal-title":"Int J Gynecol Cancer"},{"issue":"12","key":"4235_CR12","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1038\/modpathol.2013.113","volume":"26","author":"N Buza","year":"2013","unstructured":"Buza N, English DP, Santin AD, Hui P. Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice. Mod Pathol. 2013;26(12):1605\u201312. https:\/\/doi.org\/10.1038\/modpathol.2013.113.","journal-title":"Mod Pathol"},{"issue":"1","key":"4235_CR13","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ygyno.2020.07.016","volume":"159","author":"BK Erickson","year":"2020","unstructured":"Erickson BK, Najjar O, Damast S, et al. Human epidermal growth factor receptor 2 in early-stage uterine serous carcinoma: a multi-institutional cohort study. Gynecol Oncol. 2020;159(1):17\u201322. https:\/\/doi.org\/10.1016\/j.ygyno.2020.07.016.","journal-title":"Gynecol Oncol"},{"issue":"3","key":"4235_CR14","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/j.ajog.2004.10.605","volume":"192","author":"AD Santin","year":"2005","unstructured":"Santin AD, Bellone S, Siegel ER, et al. Racial differences in the overexpression of HER2\/neu: a major prognostic indicator in uterine serous papillary cancer. Am J Obstet Gynecol. 2005;192(3):813\u20138. https:\/\/doi.org\/10.1016\/j.ajog.2004.10.605.","journal-title":"Am J Obstet Gynecol"},{"issue":"20","key":"4235_CR15","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1200\/JCO.2017.76.5966","volume":"36","author":"AN Fader","year":"2018","unstructured":"Fader AN, Roque DM, Siegel E, et al. Randomized phase II trial of carboplatin\u2013paclitaxel versus carboplatin\u2013paclitaxel\u2013trastuzumab in uterine serous carcinomas that overexpress HER2\/neu. J Clin Oncol. 2018;36(20):2044\u201351. https:\/\/doi.org\/10.1200\/JCO.2017.76.5966.","journal-title":"J Clin Oncol"},{"key":"4235_CR16","unstructured":"National Comprehensive Cancer Network. Uterine Neoplasms. Version 4.2019. https:\/\/www.nccn.org\/professionals\/physician_gls\/#site. Accessed 6 Oct 2019."},{"issue":"3","key":"4235_CR17","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.ygyno.2020.09.047","volume":"159","author":"BM Slomovitz","year":"2020","unstructured":"Slomovitz BM, Broaddus R, Burke TW, et al. HER2\/neu overexpression and amplification in uterine serous carcinoma. Gynecol Oncol. 2020;159(3):744\u201351. (Sayfalar eksikse l\u00fctfen g\u00f6nder, tamamlayay\u0131m.).","journal-title":"Gynecol Oncol"},{"issue":"12","key":"4235_CR18","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1002\/gcc.22113","volume":"52","author":"N Buza","year":"2013","unstructured":"Buza N, Hui P. Marked heterogeneity of HER2\/neu gene amplification in endometrial serous carcinoma. Genes Chromosomes Cancer. 2013;52(12):1178\u201386.","journal-title":"Genes Chromosomes Cancer"},{"key":"4235_CR19","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/bjc.2017.422","volume":"118","author":"MK Halle","year":"2018","unstructured":"Halle MK, Tangen IL, Berg HF, et al. HER2 expression patterns in paired primary and metastatic endometrial cancer lesions. Br J Cancer. 2018;118:378\u201387.","journal-title":"Br J Cancer"},{"issue":"5","key":"4235_CR20","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1097\/PAS.0000000000001682","volume":"45","author":"N Banet","year":"2021","unstructured":"Banet N, Shahi M, Batista D, et al. HER2 amplification in uterine serous carcinoma and serous endometrial intraepithelial carcinoma. Am J Surg Pathol. 2021;45(5):708\u201315.","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"4235_CR21","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/modpathol.2017.124","volume":"31","author":"M K\u00f6bel","year":"2018","unstructured":"K\u00f6bel M, Rahimi K, Rambau PF, et al. An immunohistochemical algorithm for molecular classification of endometrial carcinoma: a provisional strategy. Mod Pathol. 2018;31(3):452\u201362.","journal-title":"Mod Pathol"}],"container-title":["BMC Women's Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12905-025-04235-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-025-04235-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-025-04235-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T15:49:01Z","timestamp":1781624941000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12905-025-04235-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,26]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4235"],"URL":"https:\/\/doi.org\/10.1186\/s12905-025-04235-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7820482\/v1","asserted-by":"object"}]},"ISSN":["1472-6874"],"issn-type":[{"value":"1472-6874","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,26]]},"assertion":[{"value":"9 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Hamidiye Scientific Research Ethics Committee of the Faculty of Medicine, University of Health Sciences (Approval No: 21\/213). The requirement for informed consent was waived by the same committee because the study used anonymized patient data. The study was conducted in accordance with the principles of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"53"}}